Table 2.
Authors and publication year | Design | Country | Patients | Sites | Treatment | Site | Defects (walls) | Follow-up | Effect | Evaluation | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Intervention | Control | Intervention | Control | |||||||||
Gupta G et al. 2014 [34] | Split-mouth | India | 10 | 20 | PRP + HA | HA | 10 | 10 | 1, 2, 3 | 12 mo | Positive | BOP, PD, CAL, |
Okuda K et al. 2005 [11] | Parallel | Japan | 70 | 70 | PRP + HA | HA | 35 | 35 | 2, 3 | 12 mo | Positive | GI, BOP, PD, CAL, GR, DF |
Hanna R et al. 2004 [35] | Split-mouth | US | 13 | 26 | PRP + BDX | BDX | 13 | 13 | 2, 3 | 6 mo | Positive | PD, CAL, GI, PI, REC, BOP |
Ouyang XY et al. 2006 [36] | Split-mouth | China | 10 | 17 | PRP + ABB | ABB | 9 | 8 | 2, 3 | 12 mo | Positive | PI, PD, CAL, REC, Bone defect fill |
Döri et al. 2009 [37] | Parallel | Hungary | 30 | 30 | PRP + ABB | ABB | 15 | 15 | 1,2 | 13 mo | None | PD, GR, CAL, PI, GI, BOP, |
Demir et al. 2007 [38] | Parallel | Turkey | 29 | 29 | PRP + BG | BG | 15 | 14 | 1, 2, 3 | 9 mo | None | PD, CAL, GR, PI, GI, BOP, |
Agarwal et al. 2014 [39] | Split-mouth | India | 24 | 48 | PRP + DFDBA | DFDBA | 24 | 24 | 2, 3 | 12 mo | Positive | PD, CAL, REC |
Piemontese et al. 2008 [40] | Parallel | India | 60 | 60 | PRP + DFDBA | DFDBA | 30 | 30 | 2, 3 | 12 mo | Positive | GI, PI, PD, CAL, BOP, REC, |
Harnack et al. 2009 [41] | Split-mouth | Germany | 22 | 44 | PRP + β-TCP | β-TCP | 22 | 22 | 2 | 6 mo | Positive | GI, PI, PD, CAL, BOP, |
Özdemir et al. 2012 [ 43] | Parallel | Turkey | 14 | 28 | PRP + β-TCP | β-TCP | 14 | 14 | 2,3 | 7 mo | None | PD, CAL, GI, BOP, |
Kaushick et al. 2007 [43]\ | Split-mouth | India | 10 | 20 | PRP + β-TCP + HA | β-TCP + HA | 10 | 10 | 2, 2–3, 3 | 6 mo | Positive | PD, CAL, GI, PI |
Christgau et al. 2006 [44] | Split-mouth | Germany | 25 | 50 | PRP + β-TCP + GTR | β-TCP + GTR | 25 | 25 | 2, 2–3, 3 | 12 mo | None | PI, GI, BOP, PD, GR, CAL, |
Döri, Huszar et al. 2007 [45] | Parallel | Hungary | 24 | 24 | PRP + ABB + GTR | ABB + GTR | 12 | 12 | 1-2, 2 | 12 mo | None | BOP, PD, CAL, |
Döri et al. 2007 [46] | Parallel | Hungary | 30 | 30 | PRP + NBM + GTR | NBM + GTR | 15 | 15 | 1-2, 2, 3 | 12 mo | None | PD, GR, CAL, PI, GI, BOP, |
Döri et al. 2008 [47] | Parallel | Hungary | 28 | 28 | PRP + β-TCP + GTR | β-TCP + GTR | 14 | 14 | 1-2, 2, 3 | 12 mo | Positive | PD, CAL, PI, GI, BOP, GR |
Intervention PRP group, HA hydroxyapatite, BDX bovine-derived xenograft, ABB anorganic bovine bone, BG bioactive glass, DFDBA demineralized freeze-dried bone allograft, β-TCP β-tricalcium phosphate, NBM natural bone mineral